Consolidated Statements of Changes in Shareholders' Deficit - USD ($) shares in Thousands, $ in Millions		Total	Cumulative effect adjustment	Common Stock		Additional Paid-in Capital		Retained Earnings		Retained Earnings Cumulative effect adjustment	Accumulated Other Comprehensive Loss	Treasury Stock		Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2018				761,800								319,400
Beginning balance at Dec. 31, 2018		$ (896.8)		$ 190.3		$ 2,303.6		$ 2,234.3			$ (1,030.4)	$ (4,602.3)		$ 7.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(33.5)						(32.7)						(0.8)
Other comprehensive (loss) income		(3.9)									(4.0)			0.1
Dividends accrued - Series C convertible preferred stock		(6.2)						(6.2)
Exercise/ vesting/ expense of share-based compensation (in shares)				1,300
Exercise/ vesting/ expense of share-based compensation		(1.2)		$ 0.3		(1.5)
Purchases and sales of noncontrolling interests, net of dividends paid of $0.0		0.1												0.1
Ending balance (in shares) at Mar. 31, 2019				763,100								319,400
Ending balance at Mar. 31, 2019		(941.5)		$ 190.6		2,302.1		2,195.4			(1,034.4)	$ (4,602.3)		7.1
Beginning balance (in shares) at Dec. 31, 2019				770,000								319,900
Beginning balance at Dec. 31, 2019		(983.8)	$ (2.0)	$ 192.6		2,321.2		2,138.9		$ (2.0)	(1,040.0)	$ (4,603.3)		6.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(171.9)						(171.0)						(0.9)
Other comprehensive (loss) income		(104.5)									(104.3)			(0.2)
Conversion of Series C convertible preferred stock (in shares)	[1]											(87,000)
Conversion of Series C convertible preferred stock	[1]	486.8						(710.8)				$ 1,197.6
Exercise/ vesting/ expense of share-based compensation		(9.9)		$ (0.2)		(9.7)
Exchange of common stock (in shares)	[2]			(770,000)								(232,900)
Exchange of common stock		0.0		$ (192.4)	[2]	(1,788.1)	[2]	(1,425.2)	[2]			$ 3,405.7	[2]
Ending balance (in shares) at Mar. 31, 2020	[3]			0								0
Ending balance at Mar. 31, 2020	[3]	$ (785.3)		$ 0.0		$ 523.4		$ (170.1)			$ (1,144.3)	$ 0.0		$ 5.7

[1] On December 30, 2019, Cerberus elected to convert 435,000 shares of Series C Preferred Stock, into shares of the Company’s common stock, par value U.S.$0.25 per share, conditioned on the Merger. See Note 13, Series C Convertible Preferred Stock.

[2] In January 2020, subsequent to the Merger, the Company restated its certificate of incorporation to effect a change in capitalization of the Company by changing the number of authorized shares of stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, were common stock and (ii) 25,000,000 shares, par value $1.00 per share, were preferred stock, to 1,000 shares of common stock, par value $0.01 per share. As a result of the Merger, all of the issued and outstanding common stock of the Company, being 550,890,788, were canceled and converted. See Note 19, Mergers  with Natura Cosméticos S.A., to the Consolidated Financial Statements included herein.

[3] The number of shares of Common Stock (par value $0.01 per share) outstanding at March 31, 2020 was 101.34.